Zum Hauptinhalt springen

Forschung

Um alle Therapiemöglichkeiten zum Wohle und zur Gesundheit unserer Patienten auszuschöpfen beteiligt sich das Hautkrebszentrum in großem Umfang an klinischen Studien. Eine Übersicht über alle laufenden onkologischen Studien am Universitätsklinikum Erlangen bietet die Studiendatenbank des Comprehensive Cancer Centers Erlangen-EMN .

Bei Fragen zu aktuell laufenden onkologischen Studien an der Hautklinik des Uniklinikums Erlangen stehen wir Ihnen gerne zur Verfügung. Bitte melden Sie sich telefonisch unter 09131/85-45902 (Frau Parnitzke), -45861 (Frau Simanek) oder per Mail unter onkstudienzentrale.DE@uk-erlangen.de. Wir setzten uns dann umgehend mit Ihnen in Verbindung.

Aktuelle Studien

KurztitelIndikationStudien-TitelPhaseEudra-CT:
Oncobiome Melanoma, breast-, colon- or lung-cancerGut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction
of treatment response.
22007-007847-28
Promit
PReconditioning of TumOr, Tumor Microenvironment and the
Immune System to ImmunoTherapy
Unresectable or metastatic melanomaA Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy rechallenge
in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1
or PD-1 + CTLA-4 blockade
22017-003556-23
Adoreg RegisterMM, MCC, SCC, BCCgem. §3 Nr. 1 der Veinbarung zur Dokumentation und Übermittlung von Behandlungsverläufen in ein prospektives Online-Register zur Versorgungsforschung in der dermatologischen Onkologie (ADOREG))NISXXX
MCC-TrimMerkel cell carcinomaNoninterventional cohort registry study to assess characteristics and management of patients with merkel cell carcinoma in Germany NISEU PAS register number EUPAS25338
Field-CancerizationPEK der Haut mit FeldkanzerisierungEvaluation of clinical and immunological effects of
PD-1 inhibition on actinic keratoses in patients with
advanced or metastatic cutaneous squamous cell
carcinoma in combination with a pronounced field
cancerization – An open label, prospective,
observational biomarker study of the DeCOG
NIS2021-006372-17
Combi-EUmelanoma (adjuvant setting)BRAF-/MEK-Inhibition with Dabrafenib and Trametinib in Melanoma Patients in the Adjuvant Setting: a non-interventional observatory StudyNISEUMR-18001
CemiSkinadvanced CSCCTwo cohort registry study for patients with advanced CSCC treated with Cemiplimab or other approachesNISOBS16381
InflaRx SCCOPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)22020-000864-42
BMS CA244-098MelanomA Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab-Nivolumab Fixed-dose Combination (BMS-986213) versus Nivolumab after Complete Resection of Stage III-IV Melanoma32021-001641-13
KartosMCCA Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve1b/22020-002820-35
IMA401-101MelanomA Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific
T Cell Engaging Receptor Molecule (TCER®), in Patients with Recurrent and/or Refractory Solid Tumors
1a/1b2021-004326-30 
Pfizer STARBOARD C4221016MelanomA PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND
BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS
PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATIONPOSITIVE
METASTATIC OR UNRESECTABLE LOCALLY ADVANCED
MELANOMA
32020-004850-31
BLUE-263-1201MastocytosisA Randomized, Double-Blind, Placebo-
Controlled Phase 2/3 Study of BLU-263 in
Indolent Systemic Mastocytosis
2/32020-005173-28
Biotech IO102-IO103-013MelanomAn open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma32021-004594-32